Jörg Steighardt

459 total citations
18 papers, 270 citations indexed

About

Jörg Steighardt is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jörg Steighardt has authored 18 papers receiving a total of 270 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jörg Steighardt's work include Colorectal Cancer Treatments and Studies (5 papers), Cancer Treatment and Pharmacology (3 papers) and Plant Stress Responses and Tolerance (2 papers). Jörg Steighardt is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Cancer Treatment and Pharmacology (3 papers) and Plant Stress Responses and Tolerance (2 papers). Jörg Steighardt collaborates with scholars based in Germany, Austria and Denmark. Jörg Steighardt's co-authors include Werner Roos, Gerhard Saalbach, R. Kleine, Brigitte Schumann, Katrin Viehweger, Andreas Gesell, Andreas Wienke, Michael J. Lord, Jung-Keun Suh and Jens Soukup and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Applied and Environmental Microbiology.

In The Last Decade

Jörg Steighardt

18 papers receiving 259 citations

Peers

Countries citing papers authored by Jörg Steighardt

Since Specialization

Citations

This map shows the geographic impact of Jörg Steighardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jörg Steighardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jörg Steighardt more than expected).

Fields of papers citing papers by Jörg Steighardt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jörg Steighardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jörg Steighardt. The network helps show where Jörg Steighardt may publish in the future.

Co-authorship network of co-authors of Jörg Steighardt

This figure shows the co-authorship network connecting the top 25 collaborators of Jörg Steighardt. A scholar is included among the top collaborators of Jörg Steighardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jörg Steighardt. Jörg Steighardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial 2021 ·BMC Cancer ·Sebastian Krug, Thomas Kegel, Thomas M. Gress, Anja Rinke, Leonidas Apostolidis, Henning Jann, Alexander König, Dieter Hörsch, Jörg Schrader, Thomas J. Ettrich, Michael Richter, Jörg Steighardt, Patrick Michl	3
2	Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma 2020 ·JAMA Oncology ·Hans‐Joachim Schmoll, Lars H. Lindner, Peter Reichardt, (unknown), Hans‐Georg Kopp, Torsten Keßler, Regine Mayer‐Steinacker, Jörn Rüssel, Gerlinde Egerer, Martina Crysandt, Bernd Kasper, Dietger Niederwieser, Annegret Kunitz, Ekkehard Eigendorff, Iver Petersen, Jörg Steighardt, (unknown), (unknown), Alexander Stein	22
3	FOLFOX/Bevacizumab +/− Irinotecan in advanced colorectal cancer (AIO) “CHARTA”: Final results and multivariate prognostic factor analysis 2017 ·Annals of Oncology ·Hans‐Joachim Schmoll, Benjamin Garlipp, Christian Junghanß, Malte Leithäuser, Arndt Vogel, (unknown), Ulrich Kaiser, Heinz‐Gert Hoeffkes, Axel Florschütz, Jörn Rüssel, Stephan Kanzler, (unknown), Helmut Forstbauer, Thomas Göhler, Carla Hannig, Bert Hildebrandt, Jörg Steighardt, (unknown), (unknown), Alexander Stein	1
4	CHARTA: FOLFOX+bevacizumab +/- irinotecan in advanced colorectal cancer (CRC)—Final results of the randomized phase II trial of the AIO (KRK 0209). 2017 ·Journal of Clinical Oncology ·Hans‐Joachim Schmoll, Benjamin Garlipp, Christian Junghanß, (unknown), Arndt Vogel, (unknown), Ulrich Kaiser, Heinz‐Gert Hoeffkes, Axel Florschütz, Jörn Rüssel, Stephan Kanzler, (unknown), Helmut Forstbauer, (unknown), Carla Hannig, Bert Hildebrandt, Jörg Steighardt, (unknown), (unknown), Alexander Stein	7
5	“CHARTA”: FOLFOX/Bevacizumab vs. FOLFOXIRI/Bevacizumab in advanced colorectal cancer—Final results, prognostic and potentially predictive factors from the randomized Phase II trial of the AIO. 2017 ·Journal of Clinical Oncology ·Hans‐Joachim Schmoll, (unknown), (unknown), Benjamin Garlipp, Christian Junghanß, Malte Leithäuser, Arndt Vogel, (unknown), Ulrich Kaiser, Heinz‐Gert Hoeffkes, Axel Florschütz, Jörn Rüssel, Stephan Kanzler, (unknown), Helmut Forstbauer, (unknown), Carla Hannig, Bert Hildebrandt, Jörg Steighardt, Alexander Stein	15
6	Impact of FOLFOXIRI and bevacizumab (bev) compared to FOLFOX and bev on health related quality of life (HRQOL) in patients with metastatic colorectal cancer (MCRC): Analysis of the CHARTA-AIO 0209 trial. 2017 ·Journal of Clinical Oncology ·Julia Quidde, Hans‐Joachim Schmoll, Benjamin Garlipp, Christian Junghanß, (unknown), Arndt Vogel, (unknown), Ulrich Kaiser, Heinz‐Gert Hoeffkes, Axel Florschütz, Jörn Rüssel, Stephan Kanzler, (unknown), Helmut Forstbauer, (unknown), Carla Hannig, Bert Hildebrandt, Carsten Bokemeyer, Jörg Steighardt, Alexander Stein	1
7	Multizentrische Studie zur Hörsturztherapie – Planung und Konzeption 2016 ·HNO ·Stefan K. Plontke, Matthias Girndt, Christoph Meisner, Rudolf Probst, (unknown), Michael Richter, Jörg Steighardt, (unknown), Andreas P.M. Weber, Ingo Baumann, (unknown), Jan Löhler, Roland Laszig, (unknown), Torsten Rahne	12
8	FOLFOX / Bevacizumab (Beva) +/- Irinotecan in advanced colorectal cancer (CRC): A randomized phase II trial (AIO KRK 0209, CHARTA) 2016 ·Annals of Oncology ·Hans‐Joachim Schmoll, Benjamin Garlipp, Christian Junghanß, Malte Leithäuser, Arndt Vogel, (unknown), Ulrich Kaiser, Heinz‐Gert Hoeffkes, (unknown), (unknown), Stephan Kanzler, (unknown), Helmut Forstbauer, Thomas Göhler, Carla Hannig, Bert Hildebrandt, Jörg Steighardt, (unknown), (unknown), Alexander Stein	1
9	Adhärenz in Herzgruppen: Ein prospektiver, randomisierter Vergleich einer konventionell durchgeführten Herzgruppe zu einer Tai-Chi-Herzgruppe 2016 ·Sportverletzung · Sportschaden ·(unknown), Ulrike Weber, Andreas Wienke, (unknown), (unknown), Alexander Vogt, Ursula Müller‐Werdan, Andreas Weber, Jörg Steighardt, (unknown), Axel Schlitt	6
10	Efficiency and safety of inhalative sedation with sevoflurane in comparison to an intravenous sedation concept with propofol in intensive care patients: study protocol for a randomized controlled trial 2012 ·Trials ·Jens Soukup, (unknown), Andreas Wienke, Jörg Steighardt, Nana‐Maria Wagner, Patrick Kellner	14
11	Regulatory interaction of the Gα protein with phospholipase A₂ in the plasma membrane of Eschscholzia californica 2007 ·The Plant Journal ·(unknown), Jörg Steighardt, Andreas Gesell, (unknown), Werner Roos	19
12	Intracellular pH signals in the induction of secondary pathways – The case of Eschscholzia californica 2006 ·Journal of Plant Physiology ·Werner Roos, Katrin Viehweger, (unknown), Brigitte Schumann, (unknown), Jörg Steighardt, (unknown)	39
13	Uric Acid Is a Genuine Metabolite of Penicillium cyclopium and Stimulates the Expression of Alkaloid Biosynthesis in This Fungus 2002 ·Applied and Environmental Microbiology ·(unknown), Jörg Steighardt, Werner Roos	5
14	Selective regulatory effects of purine and pyrimidine nucleotides on vacuolar transport of amino acids11Dedicated to Prof. Dr. Martin Luckner on the occasion of his 65th birthday. 2000 ·Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·Jörg Steighardt, (unknown), Werner Roos	3
15	A redox-dependent, G-protein-coupled phospholipase A of the plasma membrane is involved in the elicitation of alkaloid biosynthesis in Eschscholtzia californica 1999 ·Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·Werner Roos, (unknown), Jörg Steighardt, (unknown), (unknown), Gerhard Saalbach	62
16	Differences in Cytotoxicity of Native and Engineered RIPs Can Be Used to Assess Their Ability to Reach the Cytoplasm 1998 ·Biochemical and Biophysical Research Communications ·(unknown), Jörg Steighardt, Raquel Hernandez, Jung-Keun Suh, (unknown), Philip J. Day, Michael J. Lord, Tomás Girbés, Jon D. Robertus	20
17	Dynamic Compartmentation of Vacuolar Amino Acids in Penicillium cyclopium 1997 ·Journal of Biological Chemistry ·Werner Roos, (unknown), Jörg Steighardt	27
18	Production and immobilization of a proteinase-reduced cyclodextrin glycosyltransferase preparation 1993 ·Applied Microbiology and Biotechnology ·Jörg Steighardt, R. Kleine	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact